Cargando…

Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2

OBJECTIVE: The aim of this study was to provide recommendations on initiating and maintaining long-acting injectable antipsychotics (LAIs) in individuals with schizophrenia/schizoaffective or bipolar disorder. METHODS: A 50-question survey comprising 916 response options was completed by 34 expert r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sajatovic, Martha, Ross, Ruth, Legacy, Susan N, Byerly, Matthew, Kane, John M, DiBiasi, Faith, Fitzgerald, Heather, Correll, Christoph U
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997122/ https://www.ncbi.nlm.nih.gov/pubmed/29922063 http://dx.doi.org/10.2147/NDT.S167485

Ejemplares similares

Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
por: Sajatovic, Martha, et al.
Publicado: (2018)

Attitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: a systematic review
por: Sajatovic, Martha, et al.
Publicado: (2017)

A Systemic Review and Experts’ Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder
por: Chou, Yuan Hwa, et al.
Publicado: (2015)

Impact on length of stay and readmission rates when converting oral to long-acting injectable antipsychotics in schizophrenia or schizoaffective disorder
por: Chou, Fabienne, et al.
Publicado: (2016)

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study
por: Citrome, Leslie, et al.
Publicado: (2013)

T236. A PROGRAM TO INCREASE THE APPROPRIATE USE OF LONG-ACTING ANTIPSYCHOTIC MEDICATIONS IN COMMUNITY SETTINGS
por: Velligan, Dawn, et al.
Publicado: (2020)

Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
por: Kane, John M., et al.
Publicado: (2021)

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
por: DEVRİMCİ ÖZGÜVEN, Halise, et al.
Publicado: (2021)

Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review
por: CORRELL, Christoph U., et al.
Publicado: (2016)

Brain structural changes in schizoaffective disorder compared to schizophrenia and bipolar disorder
por: Amann, B. L., et al.
Publicado: (2015)

Social and Neurocognitive Deficits in Remitted Patients with Schizophrenia, Schizoaffective and Bipolar Disorder
por: Dehelean, Liana, et al.
Publicado: (2021)

Cardiovascular Risk for Patients With and Without Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder
por: Rossom, Rebecca C., et al.
Publicado: (2022)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: Treatment goals and approaches to functional recovery
por: Arango, Celso, et al.
Publicado: (2023)

Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery
por: Arango, Celso, et al.
Publicado: (2023)

A Misdiagnosed Case of Schizoaffective Disorder With Bipolar Manifestations
por: Paul, Tanya, et al.
Publicado: (2021)

Impact of Cannabis Use on Long-Term Remission in Bipolar I and Schizoaffective Disorder
por: Kim, Sung-Wan, et al.
Publicado: (2015)

Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
por: Azekawa, Takaharu, et al.
Publicado: (2011)

Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review
por: Coles, Alexandria S., et al.
Publicado: (2021)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Pharmacological management of bipolar disorder: Japanese expert consensus
por: Sakurai, Hitoshi, et al.
Publicado: (2020)

The effect of long-acting injectable antipsychotics on QRISK3 in patients with bipolar disorder and schizophrenia
por: Erbasan, V., et al.
Publicado: (2023)

Unmet needs with antipsychotic treatment in schizophrenia and bipolar I disorder: patient perspectives from qualitative focus groups
por: Doane, Michael J., et al.
Publicado: (2023)

Informing DSM-5: biological boundaries between bipolar I disorder, schizoaffective disorder, and schizophrenia
por: Cosgrove, Victoria E, et al.
Publicado: (2013)

Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial
por: Huhn, Maximilian, et al.
Publicado: (2020)

Switching Between Second-Generation Antipsychotics in Patients with Schizophrenia and Schizoaffective Disorder: 10-Year Cohort Study in Brazil
por: Fulone, Izabela, et al.
Publicado: (2021)

Association of Lyme Disease and Schizoaffective Disorder, Bipolar Type: Is it Inflammation Mediated?
por: Mattingley, David William, et al.
Publicado: (2015)

Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey
por: Bessonova, Leona, et al.
Publicado: (2020)

The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach
por: Correll, Christoph U., et al.
Publicado: (2022)

PM379. Quality of Life in patients with schizophrenia or bipolar disorder receiving long-acting antipsychotics
por: Lin, Shih-Ku
Publicado: (2016)

S189. CARVING A MORE SPECIFIC SUBTYPE OF SCHIZOPHRENIA FOR GENETIC STUDIES: SPORADIC SCHIZOAFFECTIVE BIPOLAR TYPE
por: van der Merwe, Nicolaas, et al.
Publicado: (2018)

Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics
por: Kishimoto, Taishiro, et al.
Publicado: (2011)

5.3 EVIDENCE ON A TRANSDIAGNOSTIC PSYCHOSIS SPECTRUM OF SCHIZOPHRENIA, SCHIZOAFFECTIVE AND PSYCHOTIC BIPOLAR DISORDER IN THE BIPOLAR-SCHIZOPHRENIA NETWORK ON INTERMEDIATE PHENOTYPES (B-SNIP)
por: Reininghaus, Ulrich, et al.
Publicado: (2018)

Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder
por: Ichinose, Mizue, et al.
Publicado: (2021)

Assessing Patient Adherence to and Engagement With Digital Interventions for Depression in Clinical Trials: Systematic Literature Review
por: Forbes, Ainslie, et al.
Publicado: (2023)

Long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders
por: Yavuz, E., et al.
Publicado: (2022)

Long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders
por: Yavuz, E., et al.
Publicado: (2023)

Genetic utility of broadly defined bipolar schizoaffective disorder as a diagnostic concept
por: Hamshere, M. L., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_b6ol2u8o2kdl5bg7suh73bihlt